[Activated protein C, a protein at the crossroads between coagulation and inflammation].

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Medecine sciences : M/S

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1051/medsci/2011275015PMID 21609671
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].

  2011cited by this paper
• Microvascular thrombosis and multiple organ dysfunction syndrome

  2010cited by this paper
• [Dr. Jekyll and Mr. Histone: protect or kill, the duality of histones].

  2010cited by this paper
• The efficacy of activated protein C in murine endotoxemia is dependent on integrin CD11b.

  2010cited by this paper
• Statistical analysis plan of PROWESS SHOCK study

  2010cited by this paper
• Reversal of refractory septic shock with drotrecogin alpha (activated)

  2009cited by this paper
• Recombinant human activated protein C inhibits integrin-mediated neutrophil migration.

  2009cited by this paper
• Extracellular histones are major mediators of death in sepsis

  2009cited by this paper
• Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database.

  2007cited by this paper
• Endotoxemia and sepsis mortality reduction by non-anticoagulant–activated protein C

  2007cited by this paper
• Protein C concentrations in severe sepsis: an early directional change in plasma levels predicts outcome

  2006cited by this paper
• Modulation of Monocyte Function by Activated Protein C, a Natural Anticoagulant1

  2006cited by this paper
• Prescribing indications based on successful clinical trials in sepsis: A difficult exercise

  2006cited by this paper
• Sepsis in European intensive care units: Results of the SOAP study*

  2006cited by this paper
• [Coagulation factor mutations and thrombosis].

  2006cited by this paper
• Two-way interactions between inflammation and coagulation.

  2005cited by this paper
• Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation.

  2005cited by this paper
• Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: Further evidence for survival and safety and implications for early treatment*

  2005cited by this paper
• Functional Selectivity of G Protein Signaling by Agonist Peptides and Thrombin for the Protease-activated Receptor-1*[boxs]

  2005cited by this paper
• Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.

  2005cited by this paper
• Leukocyte and endothelial cell interactions in sepsis: Relevance of the protein C pathway

  2004cited by this paper
• Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective

  2003cited by this paper
• Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells

  2003cited by this paper
• Inflammation and thrombosis

  2003cited by this paper
• Expression and function of the endothelial protein C receptor in human neutrophils.

  2003cited by this paper
• Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis

  2003cited by this paper
• Activation of Endothelial Cell Protease Activated Receptor 1 by the Protein C Pathway

  2002cited by this paper
• The Lectin-like Domain of Thrombomodulin Confers Protection from Neutrophil-mediated Tissue Damage by Suppressing Adhesion Molecule Expression via Nuclear Factor κB and Mitogen-activated Protein Kinase Pathways

  2002cited by this paper
• Vitronectin Functions as a Cofactor for Rapid Inhibition of Activated Protein C by Plasminogen Activator Inhibitor-1

  2001cited by this paper
• Rationale for restoration of physiological anticoagulant pathways in patients with sepsis and disseminated intravascular coagulation

  2001cited by this paper
• Efficacy and safety of recombinant human activated protein C for severe sepsis.

  2001cited by this paper
• LPS induction of gene expression in human monocytes.

  2001cited by this paper
• Apoptosis in sepsis.

  2000cited by this paper
• Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia.

  1995cited by this paper
• Cellular regulation of the protein C pathway.

  1995cited by this paper
• Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees

  1994cited by this paper
• Protein S and C4b-Binding Protein: Components Involved in the Regulation of the Protein C Anticoagulant System

  1991cited by this paper
• Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta.

  1991cited by this paper
• Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon.

  1987cited by this paper
• The roles of protein C and thrombomodulin in the regulation of blood coagulation.

  1984cited by this paper

• Risk factors for thromboembolic events in patients hospitalized for COVID-19 pneumonia in a general ward and requiring treatment with oxygen.

  2023cites this paper
• [Haemostasis dysregulation in filovirus infections].

  2015cites this paper
• Les microparticules dans le choc septique, marqueurs pathogènes et cibles thérapeutiques potentielles

  2014cites this paper
• Sepsis: Going to the Heart of the Matter

  2012cites this paper